设计、重组融合表达及活性肠肽类似物的生物学评价新型抗菌剂。
Design, Recombinant Fusion Expression and Biological Evaluation of Vasoactive Intestinal Peptide Analogue as Novel Antimicrobial Agent.
机构信息
The Key Laboratory for Space Bioscience and Biotechnology, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, China.
出版信息
Molecules. 2017 Nov 14;22(11):1963. doi: 10.3390/molecules22111963.
Antimicrobial peptides represent an emerging category of therapeutic agents with remarkable structural and functional diversity. Modified vasoactive intestinal peptide (VIP) (VIP analogue 8 with amino acid sequence "FTANYTRLRRQLAVRRYLAAILGRR") without haemolytic activity and cytotoxicity displayed enhanced antimicrobial activities against () ATCC 25923 and () ATCC 25922 than parent VIP even in the presence of 180 mM NaCl or 50 mM MgCl₂, or in the range of pH 4-10. VIP analogue 8 was expressed as fusion protein thioredoxin (Trx)-VIP8 in BL21(DE) at a yield of 45.67 mg/L. The minimum inhibitory concentration (MIC) of the recombinant VIP analogue 8 against ATCC 25923 and ATCC 25922 were 2 μM. These findings suggest that VIP analogue 8 is a promising candidate for application as a new and safe antimicrobial agent.
抗菌肽是一类具有显著结构和功能多样性的新型治疗药物。具有无溶血活性和细胞毒性的改良血管活性肠肽 (VIP)（氨基酸序列为“FTANYTRLRRQLAVRRYLAAILGRR”的 VIP 类似物 8），对 （ATCC 25923）和 （ATCC 25922）的抗菌活性明显高于亲本 VIP，即使在存在 180 mM NaCl 或 50 mM MgCl₂ 或 pH 值为 4-10 的情况下也是如此。VIP 类似物 8 在 BL21(DE) 中作为硫氧还蛋白 (Trx)-VIP8 融合蛋白表达，产量为 45.67 mg/L。重组 VIP 类似物 8 对 （ATCC 25923）和 （ATCC 25922）的最小抑菌浓度 (MIC) 分别为 2 μM。这些发现表明，VIP 类似物 8 是一种很有前途的新型安全抗菌药物候选物。
Zotero 插件